Glukagonlignende peptid 1-receptoragonisten semaglutid

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

OriginalsprogDansk
ArtikelnummerV03190155
TidsskriftUgeskrift for Laeger
Vol/bind181
Antal sider5
ISSN0041-5782
StatusUdgivet - 2019

    Forskningsområder

  • Blood Glucose, Diabetes Mellitus, Type 2/drug therapy, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides/therapeutic use, Humans, Hypoglycemic Agents/therapeutic use

ID: 241276061